Search Results - "Hernandez Parada, J"

5PSQ-086 Evaluation of the effectiveness of bezlotoxumab on prevention of recurrent Clostridium difficile infection by Martinez Puig, P, Ruiz Arca, G, Nievas Baños, AB, Hernandez Parada, J

“…Background and importance Clostridium difficile is the most common cause of infectious diarrhoea in hospitalied patients. Immunocompromised patients usually…”
Get full text

4CPS-302 Sorafenib in hepatocarcinoma: results in a real world setting by Hernandez Parada, J, Carrasco Gomariz, M, Pérez, Á Perea, Manuel Jesús, CA

“…Background and importanceHepatocarcinoma (HCC) is the leading cause of mortality in cirrhotic patients. Sorafenib has been shown to increase survival and is…”
Get full text

6ER-025 Importance of appropriate before-and-after quasi-experimental design to evaluate the impact of antimicrobial stewardship programmes: comparative results using statistical hypothesis testing or interrupted time series analysis by Lopez Viñau Lopez, T, Saez-Torres De Vicente, M, Garcia Martinez, L, Hernandez Parada, J, Ruiz Arca, G, Perea Perez, A

“…Background and importanceMost antimicrobial stewardship programmes (ASP) use a before-and-after research design, which has a high risk of bias. Efforts to…”
Get full text

4CPS-161 Scoping review on the use of canakinumab and anakinra in interleukin-1 antagonist receptor deficiency by Hernandez Parada, J, Ruano Ruiz, JA, Sáez-Torres de Vicente, M, Gómez Arias, PJ, Gómez García, F, Isla Tejera, B

“…BackgroundDeficiency in interleukin-1 (IL-1) receptor (IL-R) antagonist (DIRA) is a rare genetic autoinflammatory disorder resulting from autsomal recessive…”
Get full text

4CPS-160 Efficacy and safety of anakinra and canakinumab for the treatment of IL-36R antagonist deficiency by Sáez-Torres de Vicente, M, Gómez Arias, PJ, Hernández Parada, J, Ruano Ruiz, J, Gómez García, F, Isla Tejera, B

“…BackgroundAlterations in the interleukin (IL)−1 pathway have been shown to be involved in the pathogenesis of some auto-inflammatory diseases. Deficiency of…”
Get full text

5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital by Lopez, TLopez Viñau, Molina, MD López Malo de, Vicente, M Sáez-Torres de, Donoso, J López-Santamaria, Torres, IReyes, Parada, J Hernández

“…BackgroundDolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents…”
Get full text